Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Flaherty

Showing results (291-300 of 580) with videos related to

Pageof 58
Sort By:
British Journal of Cancer|June 10, 2010
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapyK H T Paraiso, I V Fedorenko, L P Cantini, et al.
The American Journal of Cardiology|October 15, 1995
Effect of early enalapril therapy on left ventricular function and structure in acute myocardial infarctionS P Schulman, J L Weiss, L C Becker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2011
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancerKeith T Flaherty, Patricia M Lorusso, Angela Demichele, et al.
Journal of the American College of Cardiology|August 1, 1985
Regional wall motion improvement after coronary thrombolysis with recombinant tissue plasminogen activator: importance of coronary angioplastyE J Topol, J L Weiss, J A Brinker, et al.
Molecular Cancer Therapeutics|June 21, 2023
Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant MelanomaMcKenna Q Glasheen, Signe Caksa, Amelia G Young, et al.
Psychiatric Services (Washington, D.C.)|July 1, 2009
A national action plan for workforce development in behavioral healthMichael A Hoge, John A Morris, Gail W Stuart, et al.
Pigment Cell & Melanoma Research|February 1, 2017
MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathwayLisa Koetz-Ploch, Douglas Hanniford, Igor Dolgalev, et al.
Cancer Research|July 18, 2008
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpressionKeiran S M Smalley, Rooha Contractor, Thiennga K Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
Phase I trial of combretastatin a-4 phosphate with carboplatinJoshua H Bilenker, Keith T Flaherty, Mark Rosen, et al.
Cancer Discovery|December 28, 2014
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanomaBenchun Miao, Zhenyu Ji, Li Tan, et al.
Pageof 58

Showing results (291-300 of 580) with videos related to

Sort By:
Pageof 58
British Journal of Cancer|June 10, 2010
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapyK H T Paraiso, I V Fedorenko, L P Cantini, et al.
The American Journal of Cardiology|October 15, 1995
Effect of early enalapril therapy on left ventricular function and structure in acute myocardial infarctionS P Schulman, J L Weiss, L C Becker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2011
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancerKeith T Flaherty, Patricia M Lorusso, Angela Demichele, et al.
Journal of the American College of Cardiology|August 1, 1985
Regional wall motion improvement after coronary thrombolysis with recombinant tissue plasminogen activator: importance of coronary angioplastyE J Topol, J L Weiss, J A Brinker, et al.
Molecular Cancer Therapeutics|June 21, 2023
Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant MelanomaMcKenna Q Glasheen, Signe Caksa, Amelia G Young, et al.
Psychiatric Services (Washington, D.C.)|July 1, 2009
A national action plan for workforce development in behavioral healthMichael A Hoge, John A Morris, Gail W Stuart, et al.
Pigment Cell & Melanoma Research|February 1, 2017
MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathwayLisa Koetz-Ploch, Douglas Hanniford, Igor Dolgalev, et al.
Cancer Research|July 18, 2008
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpressionKeiran S M Smalley, Rooha Contractor, Thiennga K Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
Phase I trial of combretastatin a-4 phosphate with carboplatinJoshua H Bilenker, Keith T Flaherty, Mark Rosen, et al.
Cancer Discovery|December 28, 2014
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanomaBenchun Miao, Zhenyu Ji, Li Tan, et al.
Pageof 58